4 results
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure.Secondary:*…
The primary objectives of this study are to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for in subjects with HF and left ventricular systolic dysfunction and to characterize itspharmacokinetics (PK) after 20 weeks…
This randomized controlled trial is designed to prospectively assess the safety and efficacy of a CE-marked paclitaxel-eluting balloon only strategy versus third generation DES in the setting of a STEMI. This inferiority design serves to demonstrate…
To evaluate the safety and effectiveness of the BackBeat Moderato system.